This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Elena Viboch, partner at General Catalyst, discusses her predictions for biotech and health tech investing and how startups can grow in a more constrained economic environment.
MassBio's Luba Greenwood also discusses her decision to leave Verily in order to pursue teaching the intersection of life science and technology at Harvard.
Her illustrious career has taken her from clinician to biotech executive to university chancellor to CEO of the world’s largest foundation, yet throughout this exceptional journey, Susan Desmond-Hellmann has remained empathetic, inquisitive, and emphatically true to herself.
Israel is continuing to carve out its space as a digitalhealth hub in the Middle East. Today the Israeli government announced a $33 million grant aimed at furthering the country's foothold in digitalhealth, specifically in biotech and medicine, according to Reuters.
Whether they are digitalhealth, medical device, biotech, or pharma companies, healthtech has costly and inefficient sales processes that often stem from a lack of foundational data & insights to reach the right target markets efficiently and effectively. physicians, physician groups, hospitals, health systems, etc).
Comprehensive wellness app combines fingernail selfie technology with new circulation function and features for holistic health tracking PEACHTREE CORNERS, Ga.–(BUSINESS Premium users will retain full access to their test history and exclusive at-home exercise videos designed to help improve their blood health. monthly or $99.99
DigitalHealth Technologies ( DHTs ) have revolutionized the landscape of clinical trials, particularly in neurology research, by enabling the collection of real-world data outside traditional clinical settings.
Exec Summary: The digitalhealth IPO boom of 2021 saw a surge of companies entering the public market, but the landscape has shifted since then. Why did so many DigitalHealth companies go public in 2021? There were a confluence of factors that fueled the surge of digitalhealth companies going public in 2021: 1.
Biotech Showcase is true to its name – great companies are highlighted.” Tina Elder, Global Managing Director, EBD Group US, said, “Biotech Showcase has once again shown itself to be the premiere destination for innovators and partners to access a powerful network of industry decision-makers, media and top investors.
Co-founded by industry leaders Luis Voloch, Mark Jacobstein, and Sahil Sudeach with a background in AI, healthcare, and biotechnologyJimini Health brings together expertise from healthcare and technology to create an evidence-backed, clinician-led mental health model.
With this acquisition, Gerresheimer strengthens its European footprint with additional production sites and underpins its market position as a leading full-service provider and global partner for the pharma and biotech industries. Gerresheimer expects the acquisition to be accretive to the Group’s Adj. EBITDA margin and Adj.
There’s a gap between the supply of digitalhealth tools that hospitals and health systems offer patients, and what patients-as-consumers need for overall health and wellbeing. Nowhere in the top 10 most commonly provided digital tools is one for price transparency, cost comparing or cost estimating. .
We can see the Amazon column (second in alpha order following Alibaba) with more checkmarks (in dots) indicating the most health care activities by type compared with any other “tech giant” in the world.
Meanwhile, innovations like Hera Biotech’s non-invasive test and Ziwig Biotech’s saliva test offer hope for a quicker diagnosis. Startups like Imagendo and Syrona Health also provide digital solutions for tracking symptoms and accessing information.
Aptar DigitalHealth’s SaMD platform offers digitalhealth solutions adapted to the patient’s profile, disease state and treatment plan to empower them during their treatment journey. About Aptar DigitalHealth Aptar Pharma’s DigitalHealth division is part of AptarGroup, Inc.,
Biotech and software firms are actively investing in AI healthcare platforms capable of symptom assessment, multilingual medical guidance, and automated notetaking. Evolving the DigitalHealth Journey The considerable expense of employee benefits often fails to yield optimal returns. billion by 2033. The reason?
.” Healthcare Experts – the Critical Factor for Success in New Healthcare Products and Services While health tech, tech-enabled services, medical devices, and life sciences are abundant with innovation, the path to success is challenging. MDisrupt has raised $6.6
Chrissy Farr of CNBC during WWDC: ” Quick note that it’s 2 hours in and Apple has not used the term “digitalhealth.” I suggested that maybe ‘digitalhealth’ is now just health again. Today Jay Parkinson came in with the idea that digitalhealth really should be caretech. Why “caretech?”
These challenges underscore broader obstacles faced by biotech companies, especially those dealing with sensitive personal data and relying on one-time purchase business models. Risk of Bankruptcy Analysts have speculated that 23andMe could face bankruptcy if it fails to stabilize its finances.
2018 DigitalHealth Prediction 2: Voice technology will be the first step to personalising pharma. By the end of the year we will see the use of Virtual Assistants by patients to help interact with their health data and "transact" via voice technology to order repeat prescriptions, pain management and medication requests.
BASEL, Switzerland–(BUSINESS WIRE)–Indivi, a leading MedTech company headquartered in Basel, Switzerland, has entered into an agreement with Biogen to advance digitalhealth technology and develop digital biomarkers for Parkinson’s disease.
Several consumer surveys published to coincide with CES 2020 provide insights into the new consumer trust mindset across industries, but especially important for health engagement. The DigitalHealth Summit at CES collaborated with Kantar on a poll gauging peoples’ perspectives on trust , technology and health.
Woman-led biotech company, Sanguina, secures funding to advance accessible digitalhealth and wellness platforms PEACHTREE CORNERS, Ga.–(BUSINESS Sanguina’s flagship product, the AnemoCheck app, is a digitalhealth platform that estimates hemoglobin levels and aids users in managing anemia.
For example, the FDA created a new unit within the agency’s Center for Devices and Radiological Health , which focuses solely on digitalhealth. Bakul Patel, the Associate Center Director for DigitalHealth at the FDA, envisions a Pre-Check model similar to a TSA security line at the airport.
Together with our partners from the École Polytechnique Fédérale de Lausanne, the University of Geneva and Geneva University Hospital, the Wyss Center is poised to catalyze the unique concentration of world-class brain health research at Campus Biotech to drive clinical breakthroughs.”
Claudia Pingue, senior partner and head of the Technology Transfer Fund of CDP Venture Capital SGR , added: “Aptadir is the first biotech company born from EXTEND, National Technology Transfer hub established on the initiative of CDP Venture Capital and funded with co-investment partners, Angelini Ventures and Evotec.
–(BUSINESS WIRE)– #Biotech –Taking a people-first approach, BioscienceLA, the ecosystem accelerator for life sciences in Greater Los Angeles, has launched its inaugural Leadership Catalyst Program for trailblazers in biotechnology and related sectors.
Big Pharmas looming patent cliffs could drive outlier deals (7-8x or more) for late-stage innovators, especially in biotech-adjacent HealthTech. The higher revenue multiple for HealthTech companies reflects the fact that the healthcare market is growing rapidly and there is a lot of demand for innovative digitalhealth solutions.
It’s not new-news that consumers’ trust in pharma has eroded for years, as I pointed out here in Health Populi based on the latest Edelman Trust Barometer. What was intriguing about that research is that biotech was much more trusted than pharma, with biotech being seen as more innovative.
The acquisition immediately expands EVERSANA’s European operations and worldwide capabilities to help pharmaceutical, medical device, and emerging biotech companies globally launch products, expand market access, or solve unique geographic and market-specific challenges.
Healthcare stakeholders such as health systems, pharmaceutical companies, biotech and life sciences firms, and insurance companies serve patients as end users. Market forces drove acceleration in digitalhealth, specifically telemedicine, which were sorely needed for several years. Connect with her at [link].
Exec Summary: The digitalhealth IPO boom of 2021 saw a surge of companies entering the public market, but the landscape has shifted since then. Why did so many DigitalHealth companies go public in 2021? There were a confluence of factors that fueled the surge of digitalhealth companies going public in 2021: 1.
While many industries plummeted in the first quarter of the year, digitalhealth companies closed the first quarter of 2020 with unprecedented levels of funding. Private equity and venture capital financing of digitalhealth start-ups reached an all-time high of just over $3 billion in Q1 2020.
The current B Capital global healthcare portfolio includes over 20 companies in the US, Asia and Europe, spanning early venture to late growth venture, across healthtech, digitalhealth, biotech and medtech.
“In only seven years, Health+Commerce has built a highly respected organization providing strategic programs that reach clinician, investor and consumer audiences in the multibillion-dollar medtech, biotech and digitalhealth sectors. We look forward to supporting the agency as it continues on its growth trajectory.”
In the last month I have spoken at an event about digital therapeutics and been invited to speak at 5 more unrelated events on the same topic (note: I am not doing them all). In my world view, this constitutes a trend, particularly since I haven’t been asked to speak on this topic repeatedly before. […].
This pilot study represents a critical step in leveraging digitalhealth technology to enhance cancer treatment outcomes,” said John Wagner, M.D., The study, led by principal investigator Nitin Ohri, M.D., Chief Medical Officer, Koneksa. “By
This new fund underscores the firm’s continued commitment to driving innovation and elevating health globally through investments in digitalhealth, medical devices, life sciences, and tech-enabled care delivery. OpenLoop : An end-to-end telemedicine enablement company surpassed $100 million in annualized revenues in early 2024.
DigitalHealth Solutions: Digitalhealth solutions are gaining traction in wound care, enabling remote monitoring, telemedicine consultations, and data-driven decision-making. Innovative technologies and digitalhealth solutions can help reduce costs and improve efficiency. Subscribe Today!
These figures highlight its ability to grow profitably, a rarity in healthcare IT, and its dominance in the digital physician market, which it expects to expand 5-7% annually, with Doximity aiming to outpace that. Comparatively, the healthcare sector has lagged in recent years, but 2025 is showing signs of a turnaround. Subscribe Today!
After escaping the revolution in Iran, Sean Khozin found his way to the United States, harmonizing his passion for patients and data into a career that’s led him into startups, the FDA, and most recently J&J, where he’s now Global Head of Data Strategy – all while pursuing his love of music. The phrase “it’s […].
Bilateral partnerships of this nature not only bolster our members’ businesses on the international stage, but also spotlight the robust offerings of our local ecosystem to enterprises from other growing biotech regions such as Florida,” commented Benoit Larose, CEO of BIOQuébec. Preferential registration rates for all partnered events.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content